{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:05:02Z","timestamp":1778605502689,"version":"3.51.4"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007099","name":"San Diego State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM124637"],"award-info":[{"award-number":["R35GM124637"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bcp.2023.115751","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T11:19:13Z","timestamp":1692184753000},"page":"115751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy"],"prefix":"10.1016","volume":"216","author":[{"given":"Erica A.","family":"Steen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Basilaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taelor","family":"Getz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1837-2315","authenticated-orcid":false,"given":"Peter E.","family":"Zage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115751_b0005","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1006\/bbrc.1993.2392","article-title":"Exon structure and flanking intronic sequences of the human RET proto-oncogene","volume":"196","author":"Ceccherini","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2023.115751_b0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115751_b0015","first-page":"1378","article-title":"ret transforming gene encodes a fusion protein homologous to tyrosine kinases","volume":"7","author":"Takahashi","year":"1987","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytok. Growth Factor Rev."},{"key":"10.1016\/j.bcp.2023.115751_b0025","doi-asserted-by":"crossref","first-page":"35808","DOI":"10.1074\/jbc.M104968200","article-title":"Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site","volume":"276","author":"Anders","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115751_b0030","doi-asserted-by":"crossref","first-page":"a009134","DOI":"10.1101\/cshperspect.a009134","article-title":"Structure and physiology of the RET receptor tyrosine kinase","volume":"5","author":"Ibanez","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET Proto-oncogene in cancer and development","volume":"3","author":"Takahashi","year":"2020","journal-title":"JMA J"},{"issue":"2","key":"10.1016\/j.bcp.2023.115751_b0040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/bbrc.1993.1661","article-title":"Tyrosine kinase activity of the ret proto-oncogene products in vitro","volume":"193","author":"Miyazaki","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2023.115751_b0045","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1210\/en.2004-0922","article-title":"Minireview: RET: normal and abnormal functions","volume":"145","author":"Santoro","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2023.115751_b0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.1999.0754","article-title":"GDNF family neurotrophic factor signaling: four masters, one servant?","volume":"13","author":"Airaksinen","year":"1999","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2023.115751_b0055","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1038\/sj.onc.1209349","article-title":"RET ligand-induced internalization and its consequences for downstream signaling","volume":"25","author":"Richardson","year":"2006","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.bcp.2023.115751_b0060","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1074\/jbc.M312600200","article-title":"Identification of RET autophosphorylation sites by mass spectrometry","volume":"279","author":"Kawamoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0065","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/07853890701646256","article-title":"Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases","volume":"39","author":"Runeberg-Roos","year":"2007","journal-title":"Ann. Med."},{"key":"10.1016\/j.bcp.2023.115751_b0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2183\/pjab.98.008","article-title":"RET receptor signaling: Function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.bcp.2023.115751_b0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(03)00456-7","article-title":"RET and neuroendocrine tumors","volume":"204","author":"Ichihara","year":"2004","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2023.115751_b0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0896-6273(01)00188-X","article-title":"Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts","volume":"29","author":"Paratcha","year":"2001","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.bcp.2023.115751_b0085","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.onc.1204290","article-title":"Identification of SNT\/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction","volume":"20","author":"Kurokawa","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0090","doi-asserted-by":"crossref","first-page":"31867","DOI":"10.1074\/jbc.M110.144923","article-title":"Protein-tyrosine phosphatase SHP2 contributes to GDNF neurotrophic activity through direct binding to phospho-Tyr687 in the RET receptor tyrosine kinase","volume":"285","author":"Perrinjaquet","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0095","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1242\/jcs.203885","article-title":"Differential recruitment of E3 ubiquitin ligase complexes regulates RET isoform internalization","volume":"130","author":"Hyndman","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2023.115751_b0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jso.20277","article-title":"The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells","volume":"91","author":"Funahashi","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-16-0393","article-title":"Differential roles of RET isoforms in medullary and papillary thyroid carcinomas","volume":"24","author":"Lian","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0110","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1074\/jbc.M110.195461","article-title":"RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons","volume":"286","author":"Cabrera","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0115","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1210\/jc.2010-0771","article-title":"RET-mediated cell adhesion and migration require multiple integrin subunits","volume":"95","author":"Cockburn","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2023.115751_b0120","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/sj.onc.1202514","article-title":"Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase","volume":"18","author":"Murakami","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0125","doi-asserted-by":"crossref","first-page":"34618","DOI":"10.1074\/jbc.M203580200","article-title":"The long and short isoforms of Ret function as independent signaling complexes","volume":"277","author":"Tsui-Pierchala","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0130","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41388-019-1068-z","article-title":"GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion","volume":"39","author":"Crupi","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.onc.1201199","article-title":"Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain","volume":"15","author":"Pasini","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.onc.1200831","article-title":"Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations","volume":"14","author":"Rossel","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0145","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1038\/sj.onc.1202742","article-title":"Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma","volume":"18","author":"Iwashita","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000012118","article-title":"Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas","volume":"58","author":"Le Hir","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.bcp.2023.115751_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2020.02.004","article-title":"RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma","volume":"142","author":"Moodley","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djp456","article-title":"Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves","volume":"102","author":"Gil","year":"2010","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2023.115751_b0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0170","doi-asserted-by":"crossref","first-page":"11749","DOI":"10.1074\/jbc.M114.619833","article-title":"A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis","volume":"290","author":"Bagheri-Yarmand","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.bcp.2023.115751_b0175","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1242\/dev.01421","article-title":"Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis","volume":"131","author":"Jain","year":"2004","journal-title":"Development"},{"issue":"7520","key":"10.1016\/j.bcp.2023.115751_b0180","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature13498","article-title":"The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function","volume":"514","author":"Fonseca-Pereira","year":"2014","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.bcp.2023.115751_b0185","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.2020006302","article-title":"Activation of the receptor tyrosine kinase RET improves long-term hematopoietic stem cell outgrowth and potency","volume":"136","author":"Grey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2023.115751_b0190","first-page":"137S","article-title":"The effect of the ret- mutation on the normal development of the central and parasympathetic nervous systems","volume":"Suppl 1","author":"Marcos","year":"1996","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.832317","article-title":"Multiple Roles of Ret Signalling During Enteric Neurogenesis","volume":"15","author":"Natarajan","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2023.115751_b0200","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/sj.onc.1201016","article-title":"The expression of RET and its multiple splice forms in developing human kidney","volume":"14","author":"Ivanchuk","year":"1997","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.bcp.2023.115751_b0205","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1101\/gad.205001","article-title":"Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis","volume":"15","author":"de Graaff","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2023.115751_b0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0167-4781(03)00068-X","article-title":"3\u2019 Splicing variants of ret receptor tyrosine kinase are differentially expressed in mouse embryos and in adult mice","volume":"1627","author":"Lee","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"issue":"6461","key":"10.1016\/j.bcp.2023.115751_b0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/367380a0","article-title":"Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret","volume":"367","author":"Schuchardt","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0225","first-page":"1005","article-title":"Expression of the c-ret proto-oncogene during mouse embryogenesis","volume":"119","author":"Pachnis","year":"1993","journal-title":"Dev. Camb. Engl."},{"key":"10.1016\/j.bcp.2023.115751_b0230","doi-asserted-by":"crossref","first-page":"15667","DOI":"10.3390\/ijms232415667","article-title":"A new transgenic tool to study the ret signaling pathway in the enteric nervous system","volume":"23","author":"Bandla","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115751_b0235","first-page":"5151","article-title":"Requirement of signalling by receptor tyrosine kinase RET for the directed migration of enteric nervous system progenitor cells during mammalian embryogenesis","volume":"129","author":"Natarajan","year":"2002","journal-title":"Dev Camb Engl"},{"key":"10.1016\/j.bcp.2023.115751_b0240","first-page":"568","article-title":"A genetic study of Hirschsprung disease","volume":"46","author":"Badner","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcp.2023.115751_b0245","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/00008480-200012000-00017","article-title":"Genetics of Hirschsprung disease","volume":"12","author":"Parisi","year":"2000","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.bcp.2023.115751_b0250","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1006\/dbio.2001.0557","article-title":"Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase","volume":"243","author":"Tang","year":"2002","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0255","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ydbio.2007.04.051","article-title":"PTEN modulates GDNF\/RET mediated chemotaxis and branching morphogenesis in the developing kidney","volume":"307","author":"Kim","year":"2007","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0260","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4161\/org.6.4.12680","article-title":"GDNF\/Ret signaling and renal branching morphogenesis: From mesenchymal signals to epithelial cell behaviors","volume":"6","author":"Costantini","year":"2010","journal-title":"Organogenesis"},{"key":"10.1016\/j.bcp.2023.115751_b0265","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ng.476","article-title":"Etv4 and Etv5 are required downstream of GDNF and Ret for kidney branching morphogenesis","volume":"41","author":"Lu","year":"2009","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.bcp.2023.115751_b0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s001090050065","article-title":"Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin","volume":"74","author":"Takaya","year":"1996","journal-title":"J. Mol. Med. (Berl)"},{"issue":"6126","key":"10.1016\/j.bcp.2023.115751_b0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/328170a0","article-title":"A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases","volume":"328","author":"Fusco","year":"1987","journal-title":"Nature"},{"issue":"6428","key":"10.1016\/j.bcp.2023.115751_b0280","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115751_b0285","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2023.115751_b0290","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1158\/0008-5472.CAN-08-4425","article-title":"Transcript level modulates the inherent oncogenicity of RET\/PTC oncoproteins","volume":"69","author":"Richardson","year":"2009","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0295","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115751_b0300","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115751_b0305","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2023.115751_b0310","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/leu.2012.109","article-title":"RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation","volume":"26","author":"Ballerini","year":"2012","journal-title":"Leukemia"},{"issue":"51","key":"10.1016\/j.bcp.2023.115751_b0315","doi-asserted-by":"crossref","first-page":"29654","DOI":"10.18632\/oncotarget.25664","article-title":"RET fusions observed in lung and colorectal cancers are sensitive to ponatinib","volume":"9","author":"Gozgit","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2023.115751_b0320","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2023.115751_b0325","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115751_b0330","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/PAS.0000000000001133","article-title":"Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: a report of 17 cases","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bcp.2023.115751_b0335","doi-asserted-by":"crossref","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2023.115751_b0340","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2023.115751_b0350","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.bcp.2023.115751_b0355","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Le Rolle","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115751_b0360","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-17-0325","article-title":"Advances in the management of MEN 2","volume":"25","author":"Wells","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0365","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/MCB.15.3.1613","article-title":"Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations","volume":"15","author":"Asai","year":"1995","journal-title":"Mol. Cell Biol."},{"issue":"5196","key":"10.1016\/j.bcp.2023.115751_b0370","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1126\/science.7824936","article-title":"Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B","volume":"267","author":"Santoro","year":"1995","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.bcp.2023.115751_b0375","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/sj.onc.1201759","article-title":"Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation","volume":"16","author":"Bongarzone","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0380","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1158\/0008-5472.CAN-06-0884","article-title":"RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B","volume":"66","author":"Cranston","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0385","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1158\/0008-5472.CAN-06-3329","article-title":"Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B","volume":"66","author":"Gujral","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0390","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET Mutation Consortium","volume":"276","author":"Eng","year":"1996","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.bcp.2023.115751_b0395","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"13","key":"10.1016\/j.bcp.2023.115751_b0400","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0405","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10689-006-6990-x","article-title":"The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma \u2013 only phenotype with incomplete penetrance: implications for screening and management of carrier status","volume":"5","author":"Dabir","year":"2006","journal-title":"Fam. Cancer"},{"issue":"32","key":"10.1016\/j.bcp.2023.115751_b0410","doi-asserted-by":"crossref","first-page":"33993","DOI":"10.18632\/oncotarget.4992","article-title":"RET mutation p. S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115751_b0415","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/ERC-18-0056","article-title":"Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis","volume":"25","author":"Vuong","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0420","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2023.115751_b0425","first-page":"2041","article-title":"RET proto-oncogene point mutations in sporadic neuroendocrine tumors","volume":"81","author":"Komminoth","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bcp.2023.115751_b0430","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","article-title":"GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors","volume":"73","author":"Morandi","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0435","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.1158\/0008-5472.CAN-07-2343","article-title":"A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET\/GFR alpha 1 receptor up-regulation in breast cancer","volume":"67","author":"Esseghir","year":"2007","journal-title":"Cancer Res."},{"issue":"33","key":"10.1016\/j.bcp.2023.115751_b0440","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/onc.2010.209","article-title":"Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance","volume":"29","author":"Plaza-Menacho","year":"2010","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2023.115751_b0445","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/emmm.201302625","article-title":"Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells","volume":"5","author":"Gattelli","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2023.115751_b0450","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10911-020-09445-4","article-title":"Ret receptor has distinct alterations and functions in breast cancer","volume":"25","author":"Gattelli","year":"2020","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0455","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/147323000803600406","article-title":"The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer","volume":"36","author":"Zeng","year":"2008","journal-title":"J. Int. Med. Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0460","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.surg.2005.07.007","article-title":"Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers","volume":"138","author":"Ito","year":"2005","journal-title":"Surgery"},{"issue":"23","key":"10.1016\/j.bcp.2023.115751_b0465","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/onc.2016.483","article-title":"Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma","volume":"36","author":"Amit","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0470","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-17-0528","article-title":"RET signaling in prostate cancer","volume":"23","author":"Ban","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0475","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fphys.2018.01873","article-title":"GDNF and the RET receptor in cancer: new insights and therapeutic potential","volume":"9","author":"Mulligan","year":"2018","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0480","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/1759-7714.12603","article-title":"Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases","volume":"9","author":"Tan","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0485","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jnci\/djy110","article-title":"Transcriptome characterization of matched primary breast and brain metastatic tumors to detect novel actionable targets","volume":"111","author":"Vare\u0161lija","year":"2019","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2023.115751_b0490","first-page":"1291","article-title":"Specific expression of the ret proto-oncogene in human neuroblastoma cell lines","volume":"5","author":"Ikeda","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0495","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10555-021-10001-7","article-title":"Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology","volume":"41","author":"Rozen","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2023.115751_b0500","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1038\/s41467-018-06916-5","article-title":"Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration","volume":"9","author":"McFarland","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115751_b0505","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0510","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/mcpr.1998.0181","article-title":"Absence of MEN2A- or 2B-type RET mutations in primary neuroblastoma tumour tissue","volume":"12","author":"Peaston","year":"1998","journal-title":"Mol. Cell. Probes"},{"issue":"3","key":"10.1016\/j.bcp.2023.115751_b0515","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF02185773","article-title":"No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma","volume":"97","author":"Hofstra","year":"1996","journal-title":"Hum. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0520","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1349-7006.1990.tb02566.x","article-title":"Expression of ret proto-oncogene in human neuroblastomas","volume":"81","author":"Nagao","year":"1990","journal-title":"Jpn. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0525","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ijc.2910540404","article-title":"trk and ret proto-oncogene expression in human neuroblastoma specimens: high frequency of trk expression in non-advanced stages","volume":"54","author":"Borrello","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2023.115751_b0530","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pbc.21288","article-title":"Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma","volume":"50","author":"Shimada","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0535","first-page":"2158","article-title":"Glial cell line-derived neurotrophic factor\/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR\u03b1-1, and GFR\u03b1-2","volume":"58","author":"Hishiki","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2023.115751_b0540","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711720305","article-title":"Expression of the RET Proto-oncogene product in human normal and neoplastic tissues of neural crest origin","volume":"172","author":"Nakamura","year":"1994","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2023.115751_b0545","first-page":"5399","article-title":"Expression of Multiple Endocrine Neoplasia 2B RET in Neuroblastoma Cells Alters Cell Adhesion in Vitro, Enhances Metastatic Behavior in Vivo, and Activates Jun Kinase","volume":"57","author":"Marshall","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0550","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1535-7163.MCT-07-0568","article-title":"Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium","volume":"7","author":"Beaudry","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2023.115751_b0555","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/cncr.25017","article-title":"A novel therapeutic combination for neuroblastoma: The VEGFR\/EGFR\/RET inhibitor vandetanib with 13-cis-retinoic acid","volume":"116","author":"Zage","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0560","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/bjc.1993.94","article-title":"Neuroblastoma in a transgenic mouse carrying a metallothionein\/ret fusion gene","volume":"67","author":"Iwamoto","year":"1993","journal-title":"Br. J. Cancer"},{"issue":"61","key":"10.1016\/j.bcp.2023.115751_b0565","doi-asserted-by":"crossref","first-page":"104090","DOI":"10.18632\/oncotarget.22011","article-title":"Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115751_b0930","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol."},{"issue":"1-2","key":"10.1016\/j.bcp.2023.115751_b0935","doi-asserted-by":"crossref","first-page":"13","DOI":"10.18632\/genesandcancer.97","article-title":"Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B","volume":"7","author":"Woodfield","year":"2016","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2023.115751_b0570","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbagen.2016.06.017","article-title":"Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth","volume":"1860","author":"Ruan","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2023.115751_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-8993(03)02837-3","article-title":"Mitogenic effect of glial cell line-derived neurotrophic factor is dependent on the activation of p70S6 kinase, but independent of the activation of ERK and up-regulation of Ret in SH-SY5Y cells","volume":"983","author":"Hirata","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2023.115751_b0580","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4196\/kjpp.2009.13.5.349","article-title":"Ape1\/Ref-1 Stimulates GDNF\/GFRalpha1-mediated Downstream Signaling and Neuroblastoma Proliferation","volume":"13","author":"Kang","year":"2009","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115751_b0585","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/1096-911X(20010101)36:1<122::AID-MPO1029>3.0.CO;2-R","article-title":"Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF\/Ret signal","volume":"36","author":"Takada","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0590","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1349-7006.2009.01143.x","article-title":"RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line","volume":"100","author":"Futami","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2023.115751_b0595","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1242\/dev.128.20.3963","article-title":"RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons","volume":"128","author":"Enomoto","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.bcp.2023.115751_b0600","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1006\/geno.2002.6860","article-title":"Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth","volume":"80","author":"Zhou","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.bcp.2023.115751_b0605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0344-0338(11)80558-3","article-title":"Ret-oncogene expression correlates with neuronal differentiation of neuroblastic tumors","volume":"191","author":"Ikuno","year":"1995","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bcp.2023.115751_b0610","first-page":"1387","article-title":"Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells","volume":"6","author":"D\u2019Alessio","year":"1995","journal-title":"Cell Growth Differ."},{"issue":"1","key":"10.1016\/j.bcp.2023.115751_b0615","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/excr.1995.1067","article-title":"Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis","volume":"217","author":"Bunone","year":"1995","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2023.115751_b0620","doi-asserted-by":"crossref","unstructured":"Cerchia L, D'Alessio A, Amabile G, et al. An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic Acid-induced neuroblastoma cell differentiation. Mol Cancer Res 2006; 4: 481\u20138. 10.1158\/1541-7786.MCR-06-0050.","DOI":"10.1158\/1541-7786.MCR-06-0050"},{"key":"10.1016\/j.bcp.2023.115751_b0625","doi-asserted-by":"crossref","unstructured":"Oppenheimer O, Cheung NK, Gerald WL. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007;6(4):1300-1309. 10.1158\/1535-7163.MCT-06-0587.","DOI":"10.1158\/1535-7163.MCT-06-0587"},{"key":"10.1016\/j.bcp.2023.115751_b0630","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/jmg.37.11.817","article-title":"Multiple Endocrine Neoplasia type 2 and RET: from neoplasia to neurogenesis","volume":"37","author":"Hansford","year":"2000","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bcp.2023.115751_b0635","doi-asserted-by":"crossref","first-page":"29886","DOI":"10.1074\/jbc.M600473200","article-title":"Engineering the recruitment of phosphotyrosine binding domain-containing adaptor proteins reveals distinct roles for RET receptor-mediated cell survival","volume":"281","author":"Lundgren","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0640","first-page":"99","article-title":"The role of the ShcD and RET interaction in neuroblastoma survival and migration","volume":"13","author":"Mabruk","year":"2018","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bcp.2023.115751_b0645","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/cancers10040113","article-title":"ALK in Neuroblastoma: Biological and Therapeutic Implications","volume":"10","author":"Trigg","year":"2018","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.bcp.2023.115751_b0650","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.18632\/oncotarget.1883","article-title":"Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma","volume":"5","author":"Cazes","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115751_b0655","doi-asserted-by":"crossref","unstructured":"Lambertz I, Kumps C, Claeys S, et al. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Clin Cancer Res 2015; 21: 3327-3339. 10.1158\/1078-0432.CCR-14-2024.","DOI":"10.1158\/1078-0432.CCR-14-2024"},{"issue":"11","key":"10.1016\/j.bcp.2023.115751_b0660","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41388-017-0039-5","article-title":"Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis","volume":"37","author":"Lopez-Delisle","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115751_b0665","first-page":"263","article-title":"RET receptor expression and interaction with TRK receptors in neuroblastomas","volume":"44","author":"Tetri","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2023.115751_b0670","doi-asserted-by":"crossref","unstructured":"Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, Andr\u00e8 F, Curigliano G. Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clin Cancer Res 2020; 26: 6102-6111. 10.1158\/1078-0432.CCR-20-1587.","DOI":"10.1158\/1078-0432.CCR-20-1587"},{"issue":"2","key":"10.1016\/j.bcp.2023.115751_b0675","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2023.115751_b0680","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115751_b0685","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115751_b0690","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bcp.2023.115751_b0695","doi-asserted-by":"crossref","unstructured":"Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11: 3369-76. 10.1158\/1078-0432.CCR-04-1923.","DOI":"10.1158\/1078-0432.CCR-04-1923"},{"key":"10.1016\/j.bcp.2023.115751_b0700","first-page":"1403","article-title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global","volume":"35","author":"Gautschi","year":"2017","journal-title":"Multicenter RET Registry. J Clin Oncol"},{"key":"10.1016\/j.bcp.2023.115751_b0705","doi-asserted-by":"crossref","first-page":"T53","DOI":"10.1530\/ERC-17-0297","article-title":"Novel targeted therapeutics for MEN2","volume":"25","author":"Redaelli","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0710","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0715","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0720","doi-asserted-by":"crossref","unstructured":"Bradford D, Larkins E, Mushti SL, Rodriguez L, Skinner AM, Helms WS, Price LSL, Zirkelbach JF, Li Y, Liu J, Charlab R, Turcu FR, Liang D, Ghosh S, Roscoe D, Philip R, Zack-Taylor A, Tang S, Kluetz PG, Beaver JA, Pazdur R, Theoret MR, Singh H. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clin Cancer Res 2021; 27: 2130-2135. 10.1158\/1078-0432.CCR-20-3558.","DOI":"10.1158\/1078-0432.CCR-20-3558"},{"key":"10.1016\/j.bcp.2023.115751_b0725","doi-asserted-by":"crossref","unstructured":"Kim J, Bradford D, Larkins E, Pai-Scherf LH, Chatterjee S, Mishra-Kalyani PS, Wearne E, Helms WS, Ayyoub A, Bi Y, Sun J, Charlab R, Liu J, Zhao H, Liang D, Ghosh S, Philip R, Pazdur R, Theoret MR, Beaver JA, Singh H. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions. Clin Cancer Res 2021; 27: 5452-5456. 10.1158\/1078-0432.CCR-21-0967.","DOI":"10.1158\/1078-0432.CCR-21-0967"},{"key":"10.1016\/j.bcp.2023.115751_b0730","doi-asserted-by":"crossref","first-page":"128149","DOI":"10.1016\/j.bmcl.2021.128149","article-title":"Discovery and optimization of selective RET inhibitors via scaffold hopping","volume":"47","author":"Luo","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2023.115751_b0735","doi-asserted-by":"crossref","unstructured":"Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov 2018; 8: 836-849. 10.1158\/2159-8290.CD-18-0338.","DOI":"10.1158\/2159-8290.CD-18-0338"},{"key":"10.1016\/j.bcp.2023.115751_b0740","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0745","first-page":"691","article-title":"The Multi-Kinase Inhibitor Vandetanib with 13-cis-Retinoic Acid: A Novel Therapeutic Combination for Neuroblastoma","volume":"52","author":"Zage","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2023.115751_b0750","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pbc.21535","article-title":"Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program","volume":"51","author":"Maris","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0755","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1593\/neo.09166","article-title":"In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model","volume":"11","author":"Zhang","year":"2009","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0760","doi-asserted-by":"crossref","first-page":"e95628","DOI":"10.1371\/journal.pone.0095628","article-title":"Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis","volume":"9","author":"Calero","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115751_b0765","doi-asserted-by":"crossref","unstructured":"Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res 2011; 17: 5113-22. 10.1158\/1078-0432.CCR-11-0237.","DOI":"10.1158\/1078-0432.CCR-11-0237"},{"issue":"1","key":"10.1016\/j.bcp.2023.115751_b0770","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3892\/ijo.2016.3792","article-title":"Dual inhibition using cabozantinib overcomes HGF\/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors","volume":"50","author":"Daudigeos-Dubus","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2023.115751_b0775","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00280-015-2871-z","article-title":"Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition","volume":"76","author":"Zhang","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115751_b0780","doi-asserted-by":"crossref","first-page":"e27077","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0785","doi-asserted-by":"crossref","first-page":"e28317","DOI":"10.1002\/pbc.28317","article-title":"Cabozantinib for relapsed neuroblastoma: Single institution case series","volume":"67","author":"Perisa","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0790","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2023.115751_b0795","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/pbc.24004","article-title":"Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth","volume":"59","author":"Kakodkar","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0800","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/cbt.19603","article-title":"Sorafenib inhibits endogenous and IL-6\/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis","volume":"13","author":"Yang","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2023.115751_b0805","doi-asserted-by":"crossref","unstructured":"Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res 2012; 18: 6011-22. 10.1158\/1078-0432.CCR-11-3284.","DOI":"10.1158\/1078-0432.CCR-11-3284"},{"key":"10.1016\/j.bcp.2023.115751_b0810","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pbc.25548","article-title":"Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group","volume":"62","author":"Kim","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0815","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/cam4.784","article-title":"Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases","volume":"5","author":"Okada","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2023.115751_b0820","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10637-016-0387-y","article-title":"The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma","volume":"34","author":"Whittle","year":"2016","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2023.115751_b0825","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2174\/1568009617666161122145219","article-title":"In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies","volume":"17","author":"Singh","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2023.115751_b0830","doi-asserted-by":"crossref","unstructured":"Sidarovich V, De Mariano M, Aveic S, Pancher M, Adami V, Gatto P, Pizzini S, Pasini L, Croce M, Parodi F, Cimmino F, Avitabile M, Emionite L, Cilli M, Ferrini S, Pagano A, Capasso M, Quattrone A, Tonini GP, Longo L. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy. Mol Cancer Ther 2018; 17: 1405-1415. 10.1158\/1535-7163.MCT-17-0841.","DOI":"10.1158\/1535-7163.MCT-17-0841"},{"issue":"59","key":"10.1016\/j.bcp.2023.115751_b0835","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.18632\/oncotarget.27259","article-title":"The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo","volume":"10","author":"Flynn","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115751_b0840","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2019.05.011","article-title":"Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling","volume":"457","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2023.115751_b0845","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Results Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0850","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41416-020-0905-8","article-title":"Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS\/MAPK, PI3K\/Akt\/mTOR and Fos\/Jun pathways","volume":"123","author":"Subramonian","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0855","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2021.05.023","article-title":"Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies","volume":"153","author":"Geoerger","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2023.115751_b0860","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2017.04.022","article-title":"The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model","volume":"400","author":"Lu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2023.115751_b0865","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3389\/fonc.2019.00579","article-title":"Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells","volume":"9","author":"Alam","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115751_b0870","doi-asserted-by":"crossref","first-page":"e27055","DOI":"10.1002\/pbc.27055","article-title":"Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma","volume":"65","author":"Heath","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"16 Suppl","key":"10.1016\/j.bcp.2023.115751_b0875","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1158\/1538-7445.AM2020-5402","article-title":"Inhibition of RET via BLU-667 in an in vitro model of neuroblastoma","volume":"80","author":"Gutierrez","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115751_b0880","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.012","article-title":"Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma","volume":"158","author":"Shankar","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2023.115751_b0885","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1200\/PO.19.00401","article-title":"Activity of the highly specific RET inhibitor selpercatinib (LOXO-292) in pediatric patients with tumors harboring RET gene alterations","author":"Ortiz","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"suppl 15","key":"10.1016\/j.bcp.2023.115751_b0890","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2021.39.15_suppl.10009","article-title":"Oral selpercatinib in pediatric patients with advanced RET-altered solid or primary CNS tumors: preliminary results from the phase 1\/2 LIBRETTO-121 trial","volume":"39","author":"Morgenstern","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"0","key":"10.1016\/j.bcp.2023.115751_b0895","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1039\/CT9222100614","article-title":"LXXI.\u2014The molecular configurations of polynuclear aromatic compounds. Part I. The resolution of \u03b3-6 : 6\u2032-dinitro- and 4 : 6 : 4\u2032 : 6\u2032-tetranitro-diphenic acids into optically active components","volume":"121","author":"Christie","year":"1922","journal-title":"J. Chem. Soc. Trans."},{"key":"10.1016\/j.bcp.2023.115751_b0900","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1021\/jm200584g","article-title":"Assessing atropisomer axial chirality in drug discovery and development","volume":"54","author":"LaPlante","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0905","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.orglett.8b00579","article-title":"Enantioselective synthesis of pyrrolopyrimidine scaffolds through cation-directed nucleophilic aromatic substitution","volume":"20","author":"Cardenas","year":"2018","journal-title":"Org. Lett."},{"key":"10.1016\/j.bcp.2023.115751_b0910","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/acs.accounts.2c00500","article-title":"Atropisomerism in the Pharmaceutically Relevant Realm","volume":"55","author":"Basilaia","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bcp.2023.115751_b0915","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4155\/fmc-2017-0152","article-title":"Atropisomerism in medicinal chemistry: challenges and opportunities","volume":"10","author":"Toenjes","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bcp.2023.115751_b0920","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1074-5521(99)80118-5","article-title":"Structural Basis for Selective Inhibition of Src Family Kinases by PP1","volume":"6","author":"Liu","year":"1999","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bcp.2023.115751_b0925","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1021\/acschembio.9b00407","article-title":"Leveraging atropisomerism to obtain a selective inhibitor of RET kinase with secondary activities toward EGFR mutants","volume":"14","author":"Toenjes","year":"2019","journal-title":"ACS Chem. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223003428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:45:01Z","timestamp":1757771101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223003428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":187,"alternative-id":["S0006295223003428"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115751","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115751"}}